Boehringer Ingelheim has acquired all shares of ViraTherapeutics (VT), a biopharmaceutical company specializing in the development of oncolytic viral therapies. According to the company, the deal has a total value of € 10 million. ViraTherapeutics was founded in 2013 as a spin-out of the Medical University of Innsbruck focused on the development of oncolytic cancer vaccines based on a chimeric virus derived from the vesicular stomatitis virus (VSV). The company was participated by the two venture investors EMBL Ventures and the Boehringer Ingelheim Venture Fund (BIVF). VT’s lead candidate VSV-GP is being investigated alone and in combination with other therapies, and it has shown promising results in pre-clinical models.